Issues
-
Cover Image
Cover Image
About the Cover
Patients with familial adenomatous polyposis (FAP) have inflamed colons and have a high risk of colon cancer. These patients have defective retinoic acid (RA) metabolism that produces a local deficit of RA in the tumor milieu. Using a mouse model of FAP, decreased or absent RA encouraged disease progression, but inhibiting an enzyme that catabolizes RA ameliorated disease. One of the effects of increasing RA was to dampen the inflammatory phenotype of gut dendritic cells, and these cells were found to be crucial for adenoma formation. Read more in the article by Penny and colleagues starting on page 917 of this issue. The confocal microscopy image is of an FAP polyp, with red labeling an inhibitor of the RA metabolic pathway, CTBP1, and green denoting dendritic cells labeled with DC-SIGN (photo by HL Penny, of the Edgar G Engleman lab). Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
What We’re Reading
Masters of Immunology
Cancer Immunology Miniatures
Priority Brief
Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
Research Articles
Restoring Retinoic Acid Attenuates Intestinal Inflammation and Tumorigenesis in APCMin/+ Mice
MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.